Table 2.
Control | Treatment | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | F Value | p Value | |||||
Fold Change | Fold Change | Fold Change | Fold Change | Treatment | Sex | Interaction | Treatment | Sex | Interaction | |
SNAP29 | 1.03 ± 0.10 | 1.02 ± 0.12 | 0.95 ± 0.11 | 0.62±0.14 *,# | 24.64 | 12.36 | 10.95 & | <0.0001 | 0.0022 | 0.0035 |
UFD1L | 1.01 ± 0.07 | 1.02 ± 0.06 | 0.61 ± 0.08 * | 0.65±0.08 * | 167.00 | 0.7042 | 0.2535 | <0.0001 | 0.4113 | 0.6201 |
ZDHHC8 | 1.04 ± 0.05 | 1.05 ± 0.07 | 0.95 ± 0.07 * | 0.58±0.06 *,# | 131.40 | 41.09 | 46.23 & | <0.0001 | <0.0001 | <0.0001 |
PDLIM5 | 1.01 ± 0.08 | 1.05 ± 0.10 | 0.71 ± 0.10 * | 0.82±0.14 * | 36.64 | 2.935 | 0.639 | <0.0001 | 0.1022 | 0.4334 |
HSPA1A | 1.06 ± 0.10 | 0.99 ± 0.07 | 0.54 ± 0.11 * | 0.56±0.09 * | 154.30 | 0.4273 | 1.385 | <0.0001 | 0.5207 | 0.2531 |
PTEN | 0.99 ± 0.08 | 1.03 ± 0.09 | 0.63 ± 0.11 * | 0.67±0.12 * | 75.86 | 0.94 | 0.00 | <0.0001 | 0.3447 | 1.0000 |
GDNF | 1.01 ± 0.07 | 0.98 ± 0.05 | 0.65 ± 0.06 * | 0.32±0.14 *,# | 204.00 | 25.41 | 17.65 & | <0.0001 | <0.0001 | 0.0004 |
SOD2 | 0.97 ± 0.06 | 0.99 ± 0.08 | 0.67 ± 0.12 * | 0.56±0.07 * | 109.10 | 1.66 | 3.46 | <0.0001 | 0.2125 | 0.0776 |
GNAS | 1.01 ± 0.09 | 1.06 ± 0.12 | 0.88 ± 0.15 | 0.70±0.14 *,# | 22.30 | 1.57 | 4.91 & | 0.0001 | 0.2247 | 0.0384 |
NOS3 | 0.96 ± 0.11 | 1.00 ± 0.04 | 0.71 ± 0.08 * | 0.93±0.15 # | 14.42 | 9.52 | 4.56 & | 0.0011 | 0.0058 | 0.0452 |
DLST | 1.01 ± 0.04 | 0.97 ± 0.06 | 0.91 ± 0.12 | 0.87±0.06 | 10.34 | 1.66 | 0.00 | 0.0043 | 0.2130 | 1.0000 |
GRIN2A | 0.97 ± 0.08 | 1.01 ± 0.06 | 1.10 ± 0.18 | 2.78±0.17 *,# | 423.70 | 317.70 | 288.20 & | <0.0001 | <0.0001 | <0.0001 |
DGKH | 1.01 ± 0.04 | 1.06 ± 0.09 | 2.14 ± 0.09 * | 0.72±0.06 *,# | 175.00 | 526.21 | 605.94 & | <0.0001 | <0.0001 | <0.0001 |
MT2A | 1.01 ± 0.07 | 1.02 ± 0.15 | 1.98 ± 0.07 * | 2.34±0.13 *,# | 639.50 | 16.70 | 14.94 & | 0.0010 | 0.0006 | <0.0001 |
CACNA1G | 1.04 ± 0.07 | 1.03 ± 0.06 | 2.77 ± 0.13 * | 0.75±0.12 *,# | 516.75 | 938.68 | 887.50 & | <0.0001 | <0.0001 | <0.0001 |
KCNQ | 1.00 ± 0.04 | 0.97 ± 0.08 | 2.86 ± 0.10 * | 0.72±0.11 *,# | 317.03 | 621.19 | 609.14 & | <0.0001 | <0.0001 | <0.0001 |
* p < 0.05, compared with corresponding sex control, # p < 0.05, compared with male Al2O3 NP treated mice, & p < 0.05, sex and Al2O3 NPs treatment showed interaction effect, df = 5.